Preprint / Version 2

Budgetarry impact of the incorporation of claritromycin in the treatment of infection by new coronavirus

##article.authors##

DOI:

https://doi.org/10.1590/SciELOPreprints.1026

Keywords:

Pandemics, Covid-19, Unified Health System, Budgetary Impact Analysis, Drug therapy

Abstract

Introduction: In Brazil, the use of third generation cephalosporins associated with a macrolide (azithromycin or clarithromycin), has been recommended at admission. Objective: To estimate the budgetary impact of the use of clarithromycin as a supporting macrolide in the empirical treatment scheme for patients with Severe Acute Respiratory Syndrome. Method: Budgetary Impact Analysis. Unified Health System perspective, local level. 5-year time horizon. Used the Brazilian Budget Impact Analysis Worksheet. Three alternative scenarios and one reference were analyzed. Results: The five-year cost in the reference scenario was R$ 2,504,887.92. Conclusion: The incorporation of clarithromycin in alternative scenarios may represent an average incremental cost of more than 22% of the budget available for the acquisition of azithromycin in 5 years, which may be economically unfeasible to offer to all patients in hospitals, without having loss in meeting other demands.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Posted

2020-08-04 — Updated on 2020-08-09

Versions

Section

Health Sciences